Scholar Rock seeks $275M in stock sale: After announcing the success of a pivotal clinical trial for its muscle-targeted spinal muscular atrophy treatment, Scholar Rock’s shares $SRRK skyrocketed over ...
Nearly eight years after securing a historic first approval for a spinal muscular atrophy drug, Biogen is seeking to launch a ...
Last October was an FDA approval. This October is a $68 million fundraising round. Next year, maybe a drug launch.
A three-year-old startup based on decades of research in cell depletion is betting that some of the hottest tools in oncology may work even better in other diseases. Arda Therapeutics has raised a $43 ...
As Merck builds out its immunology research lab in London, it's partnering with a local biotech startup that has remained ...
Sage Therapeutics is reeling from another mid-stage setback as its investigational medicine dalzanemdor has missed the mark ...
As it works to rebuild from an earlier gene therapy setback, Astellas is doubling down on the one-and-done modality in a new ...
Johnson & Johnson’s drug-device combo has disappointed in a late-stage test in people with an advanced form of bladder cancer but it says it is still confident in the technology's overall blockbuster ...
Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster ...
Many drug price proposals from candidates and Congress won't have much effect, analysis finds
Want to lower drug prices? Good luck. In a new report released Friday, the nonpartisan Congressional Budget Office (CBO) detailed how many of the campaign proposals mentioned by presidential nominees ...
Liquidia’s stock $LQDA rose about 10% on Monday following a win in the US Supreme Court for its treprostinil inhalation ...
The news that Pfizer has an activist isn’t a surprise. For the last few months at Endpoints News, we’ve been asking which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback